Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials

PLoS Pathogens

Volumn 9, Issue 4, 2013, Pages

  Ölschläger, Stephan ^a   Flatz, Lukas ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

DNA VACCINE; EPITOPE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; NEUTRALIZING ANTIBODY;

AMINO ACID SEQUENCE; ARENAVIRUS; HEMORRHAGIC FEVER; HUMAN; IMMUNOLOGY; LASSA VIRUS; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; T LYMPHOCYTE; VACCINATION;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ARENAVIRIDAE INFECTIONS; ARENAVIRUS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HEMORRHAGIC FEVERS, VIRAL; HUMANS; JUNIN VIRUS; VACCINATION; VACCINES, ATTENUATED; VIRAL VACCINES;

ARENAVIRUS; CANDIDA; JUNIN VIRUS;

EID: 84876872412     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003212     Document Type: Review

References (79)

1. Charrel RN, de Lamballerie X, Emonet S, (2008) Phylogeny of the genus Arenavirus. Curr Opin Microbiol 11: 362-368.
2. Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, et al. (2006) Transmission of lymphocytic choriomeningitis virus by organ transplantation. N Engl J Med 354: 2235-2249.
3. Lukashevich IS, Stelmakh TA, Golubev VP, Stchesljenok EP, Lemeshko NN, (1984) Ribonucleic acids of Machupo and Lassa viruses. Arch Virol 79: 189-203.
4. Auperin DD, Romanowski V, Galinski M, Bishop DH, (1984) Sequencing studies of pichinde arenavirus S RNA indicate a novel coding strategy, an ambisense viral S RNA. J Virol 52: 897-904.
5. Bowen MD, Peters CJ, Nichol ST, (1997) Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts. Mol Phylogenet Evol 8: 301-316.
6. Fisher-Hoch SP, (2005) Lessons from nosocomial viral haemorrhagic fever outbreaks. Br Med Bull 73-74: 123-137.
7. Flatz L, Rieger T, Merkler D, Bergthaler A, Regen T, et al. (2010) T cell-dependence of Lassa fever pathogenesis. PLoS Pathog 6: e1000836 doi:10.1371/journal.ppat.1000836.
8. Hastie KM, Kimberlin CR, Zandonatti MA, MacRae IJ, Saphire EO, (2011) Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3′ to 5′ exonuclease activity essential for immune suppression. Proc Natl Acad Sci U S A 108: 2396-2401.
9. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, et al. (1986) Lassa fever. Effective therapy with ribavirin. N Engl J Med 314: 20-26.
10. McCormick JB, King IJ, Webb PA, Johnson KM, O'Sullivan R, et al. (1987) A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis 155: 445-455.
11. Maiztegui JI, (1975) Clinical and epidemiological patterns of Argentine haemorrhagic fever. Bull World Health Organ 52: 567-575.
12. Maiztegui JI, McKee KT Jr, Barrera Oro JG, Harrison LH, Gibbs PH, et al. (1998) Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. AHF Study Group. J Infect Dis 177: 277-283.
13. Ambrosio A, Saavedra M, Mariani M, Gamboa G, Maiza A, (2011) Argentine hemorrhagic fever vaccines. Hum Vaccin 7: 694-700.
14. Jahrling PB, Peters CJ, (1984) Passive antibody therapy of Lassa fever in cynomolgus monkeys: importance of neutralizing antibody and Lassa virus strain. Infect Immun 44: 528-533.
15. Jahrling PB, (1983) Protection of Lassa virus-infected guinea pigs with Lassa-immune plasma of guinea pig, primate, and human origin. J Med Virol 12: 93-102.
16. Jahrling PB, Peters CJ, Stephen EL, (1984) Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 149: 420-427.
17. Maiztegui JI, Fernandez NJ, de Damilano AJ, (1979) Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet 2: 1216-1217.
18. Kiley MP, Lange JV, Johnson KM, (1979) Protection of rhesus monkeys from Lassa virus by immunisation with closely related Arenavirus. Lancet 2: 738.
19. Tauraso N, Shelokov A, (1965) Protection against Junin Virus by Immunization with Live Tacaribe Virus. Proc Soc Exp Biol Med 119: 608-611.
20. Coto CE, Rey E, Parodi AS, (1967) Tacaribe virus infection of guinea-pig. Virus distribution, appearance of antibodies and immunity against Junin virus infection. Arch Gesamte Virusforsch 20: 81-86.
21. Coto CE, Damonte EB, Catello MA, Weissenbacher MC, (1980) Protection of guinea pigs inoculated with Tacaribe virus against lethal doses of Junin virus. J Infect Dis 141: 389-393.
22. Weissenbacher MC, Coto CE, Calello MA, Rondinone SN, Damonte EB, et al. (1982) Cross-protection in nonhuman primates against Argentine hemorrhagic fever. Infect Immun 35: 425-430.
23. Videla C, Carballal G, Remorini P, La Torre J, (1989) Formalin inactivated Junin virus: immunogenicity and protection assays. J Med Virol 29: 215-220.
24. Lopez N, Scolaro L, Rossi C, Jacamo R, Candurra N, et al. (2000) Homologous and heterologous glycoproteins induce protection against Junin virus challenge in guinea pigs. J Gen Virol 81: 1273-1281.
25. ter Meulen J, (1999) Lassa fever: implications of T-cell immunity for vaccine development. J Biotechnol 73: 207-212.
26. Boesen A, Sundar K, Coico R, (2005) Lassa fever virus peptides predicted by computational analysis induce epitope-specific cytotoxic-T-lymphocyte responses in HLA-A2.1 transgenic mice. Clin Diagn Lab Immunol 12: 1223-1230.
27. Botten J, Alexander J, Pasquetto V, Sidney J, Barrowman P, et al. (2006) Identification of protective Lassa virus epitopes that are restricted by HLA-A2. J Virol 80: 8351-8361.
28. Klenerman P, Zinkernagel RM, (1998) Original antigenic sin impairs cytotoxic T lymphocyte responses to viruses bearing variant epitopes. Nature 394: 482-485.
29. La Posta VJ, Auperin DD, Kamin-Lewis R, Cole GA, (1993) Cross-protection against lymphocytic choriomeningitis virus mediated by a CD4+ T-cell clone specific for an envelope glycoprotein epitope of Lassa virus. J Virol 67: 3497-3506.
30. Oldstone MB, Lewicki H, Homann D, Nguyen C, Julien S, et al. (2001) Common antiviral cytotoxic t-lymphocyte epitope for diverse arenaviruses. J Virol 75: 6273-6278.
31. Meulen J, Badusche M, Satoguina J, Strecker T, Lenz O, et al. (2004) Old and New World arenaviruses share a highly conserved epitope in the fusion domain of the glycoprotein 2, which is recognized by Lassa virus-specific human CD4+ T-cell clones. Virology 321: 134-143.
32. Kotturi MF, Botten J, Sidney J, Bui HH, Giancola L, et al. (2009) A multivalent and cross-protective vaccine strategy against arenaviruses associated with human disease. PLoS Pathog 5: e1000695 doi:10.1371/journal.ppat.1000695.
33. Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, et al. (2010) A multivalent vaccination strategy for the prevention of Old World arenavirus infection in humans. J Virol 84: 9947-9956.
34. Blattman JN, Wherry EJ, Ha SJ, van der Most RG, Ahmed R, (2009) Impact of epitope escape on PD-1 expression and CD8 T-cell exhaustion during chronic infection. J Virol 83: 4386-4394.
35. Johnson PL, Kochin BF, McAfee MS, Stromnes IM, Regoes RR, et al. (2011) Vaccination alters the balance between protective immunity, exhaustion, escape, and death in chronic infections. J Virol 85: 5565-5570.
36. Albarino CG, Bird BH, Chakrabarti AK, Dodd KA, Flint M, et al. (2011) The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain. J Virol 85: 10404-10408.
37. Riedel S, (2005) Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 18: 21-25.
38. Frierson JG, (2010) The yellow fever vaccine: a history. Yale J Biol Med 83: 77-85.
39. Miller JD, van der Most RG, Akondy RS, Glidewell JT, Albott S, et al. (2008) Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines. Immunity 28: 710-722.
40. Walker DH, Johnson KM, Lange JV, Gardner JJ, Kiley MP, et al. (1982) Experimental infection of rhesus monkeys with Lassa virus and a closely related arenavirus, Mozambique virus. J Infect Dis 146: 360-368.
41. Lange JV, Mitchell SW, McCormick JB, Walker DH, Evatt BL, et al. (1985) Kinetic study of platelets and fibrinogen in Lassa virus-infected monkeys and early pathologic events in Mopeia virus-infected monkeys. Am J Trop Med Hyg 34: 999-1007.
42. Lukashevich IS, (1992) Generation of reassortants between African arenaviruses. Virology 188: 600-605.
43. Lukashevich IS, Patterson J, Carrion R, Moshkoff D, Ticer A, et al. (2005) A live attenuated vaccine for Lassa fever made by reassortment of Lassa and Mopeia viruses. J Virol 79: 13934-13942.
44. Lukashevich IS, Carrion R Jr, Salvato MS, Mansfield K, Brasky K, et al. (2008) Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates. Vaccine 26: 5246-5254.
45. Moshkoff DA, Salvato MS, Lukashevich IS, (2007) Molecular characterization of a reassortant virus derived from Lassa and Mopeia viruses. Virus Genes 34: 169-176.
46. Branco LM, Grove JN, Geske FJ, Boisen ML, Muncy IJ, et al. (2010) Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever. Virol J 7: 279.
47. McCormick JB, Mitchell SW, Kiley MP, Ruo S, Fisher-Hoch SP, (1992) Inactivated Lassa virus elicits a non protective immune response in rhesus monkeys. J Med Virol 37: 1-7.
48. Amanna IJ, Raue HP, Slifka MK, (2012) Development of a new hydrogen peroxide-based vaccine platform. Nat Med 18: 974-979.
49. Djavani M, Yin C, Xia L, Lukashevich IS, Pauza CD, et al. (2000) Murine immune responses to mucosally delivered Salmonella expressing Lassa fever virus nucleoprotein. Vaccine 18: 1543-1554.
50. Djavani M, Yin C, Lukashevich IS, Rodas J, Rai SK, et al. (2001) Mucosal immunization with Salmonella typhimurium expressing Lassa virus nucleocapsid protein cross-protects mice from lethal challenge with lymphocytic choriomeningitis virus. J Hum Virol 4: 103-108.
51. Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, et al. (1984) Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A 81: 7194-7198.
52. Mackett M, Smith GL, Moss B, (1982) Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci U S A 79: 7415-7419.
53. Thummel C, Tjian R, Grodzicker T, (1981) Expression of SV40 T antigen under control of adenovirus promoters. Cell 23: 825-836.
54. Flatz L, Hegazy AN, Bergthaler A, Verschoor A, Claus C, et al. (2010) Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity. Nat Med 16: 339-345.
55. Martina BE, van den Doel P, Koraka P, van Amerongen G, Spohn G, et al. (2011) A recombinant influenza A virus expressing domain III of West Nile virus induces protective immune responses against influenza and West Nile virus. PLoS One 6: e18995 doi:10.1371/journal.pone.0018995.
56. Dondji B, Deak E, Goldsmith-Pestana K, Perez-Jimenez E, Esteban M, et al. (2008) Intradermal NKT cell activation during DNA priming in heterologous prime-boost vaccination enhances T cell responses and protection against Leishmania. Eur J Immunol 38: 706-719.
57. Clegg JC, Lloyd G, (1987) Vaccinia recombinant expressing Lassa-virus internal nucleocapsid protein protects guineapigs against Lassa fever. Lancet 2: 186-188.
58. Auperin DD, Esposito JJ, Lange JV, Bauer SP, Knight J, et al. (1988) Construction of a recombinant vaccinia virus expressing the Lassa virus glycoprotein gene and protection of guinea pigs from a lethal Lassa virus infection. Virus Res 9: 233-248.
59. Fisher-Hoch SP, Hutwagner L, Brown B, McCormick JB, (2000) Effective vaccine for lassa fever. J Virol 74: 6777-6783.
60. Garbutt M, Liebscher R, Wahl-Jensen V, Jones S, Moller P, et al. (2004) Properties of replication-competent vesicular stomatitis virus vectors expressing glycoproteins of filoviruses and arenaviruses. J Virol 78: 5458-5465.
61. Geisbert TW, Jones S, Fritz EA, Shurtleff AC, Geisbert JB, et al. (2005) Development of a new vaccine for the prevention of Lassa fever. PLoS Med 2: e183 doi:10.1371/journal.pmed.0020183.
62. Gunther S, Feldmann H, Geisbert TW, Hensley LE, Rollin PE, et al. (2011) Management of accidental exposure to Ebola virus in the biosafety level 4 laboratory, Hamburg, Germany. J Infect Dis 204 Suppl 3: S785-S790.
63. Guy B, Guirakhoo F, Barban V, Higgs S, Monath TP, et al. (2010) Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses. Vaccine 28: 632-649.
64. Jiang X, Dalebout TJ, Bredenbeek PJ, Carrion R Jr, Brasky K, et al. (2011) Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs. Vaccine 29: 1248-1257.
65. Bredenbeek PJ, Molenkamp R, Spaan WJ, Deubel V, Marianneau P, et al. (2006) A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins. Virology 345: 299-304.
66. Pushko P, Geisbert J, Parker M, Jahrling P, Smith J, (2001) Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 75: 11677-11685.
67. Rojek JM, Sanchez AB, Nguyen NT, de la Torre JC, Kunz S, (2008) Different mechanisms of cell entry by human-pathogenic Old World and New World arenaviruses. J Virol 82: 7677-7687.
68. Huygen K, (2005) Plasmid DNA vaccination. Microbes Infect 7: 932-938.
69. Rodriguez-Carreno MP, Nelson MS, Botten J, Smith-Nixon K, Buchmeier MJ, et al. (2005) Evaluating the immunogenicity and protective efficacy of a DNA vaccine encoding Lassa virus nucleoprotein. Virology 335: 87-98.
70. McCormick JB, Webb PA, Krebs JW, Johnson KM, Smith ES, (1987) A prospective study of the epidemiology and ecology of Lassa fever. J Infect Dis 155: 437-444.
71. The World Bank (2012) Gross domestic product ranking table 2011. World development indicators. Washington: The World Bank. Available: http://data.worldbank.org/data-catalog/http://databank.worldbank.org/databank/download/GDP.pdf.
72. OPEC (2013) Market indicators as at end: December 2012. OPEC market indicators. Vienna: Organization of the Petroleum Exporting Countries. Available: http://www.opec.org/opec_web/static_files_project/media/downloads/data_graphs/MI122012.pdf.
73. Johnson KM, McCormick JB, Webb PA, Smith ES, Elliott LH, et al. (1987) Clinical virology of Lassa fever in hospitalized patients. J Infect Dis 155: 456-464.
74. Streeton JA, Desem N, Jones SL, (1998) Sensitivity and specificity of a gamma interferon blood test for tuberculosis infection. Int J Tuberc Lung Dis 2: 443-450.
75. Thomas RE, Lorenzetti DL, Spragins W, Jackson D, Williamson T, (2012) The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review. Am J Trop Med Hyg 86: 359-372.
76. Botten J, Whitton JL, Barrowman P, Sidney J, Whitmire JK, et al. (2007) HLA-A2-restricted protection against lethal lymphocytic choriomeningitis. J Virol 81: 2307-2317.
77. Kotturi MF, Swann JA, Peters B, Arlehamn CL, Sidney J, et al. (2011) Human CD8(+) and CD4(+) T cell memory to lymphocytic choriomeningitis virus infection. J Virol 85: 11770-11780.
78. Kotturi MF, Botten J, Maybeno M, Sidney J, Glenn J, et al. (2010) Polyfunctional CD4+ T cell responses to a set of pathogenic arenaviruses provide broad population coverage. Immunome Res 6: 4.
79. ter Meulen J, Badusche M, Kuhnt K, Doetze A, Satoguina J, et al. (2000) Characterization of human CD4(+) T-cell clones recognizing conserved and variable epitopes of the Lassa virus nucleoprotein. J Virol 74: 2186-2192.